Astrana Health(US:ASTH) Yahoo Finance·2025-11-18 10:07Core Insights - Astrana Health, Inc. (NASDAQ:ASTH) has received mixed opinions from analysts, with a Buy rating from Truist Financial and a lowered price target from TD Cowen [1][2] Financial Performance - For fiscal Q3 2025, Astrana Health reported a revenue growth of 99.71% year-over-year, reaching $956.05 million, which exceeded estimates by $3.22 million [2] - The company's EPS was $0.01, which fell short of the consensus estimate by $0.43 [2] Future Outlook - Management has lowered its full-year revenue guidance to a range of $3.1 billion to $3.18 billion, down from the previous range of $3.1 billion to $3.3 billion [3] - Adjusted EBITDA guidance was also reduced to a range of $200 million to $210 million, from the previous range of $215 million to $225 million [3] - The reduced outlook is attributed to anticipated headwinds in the Medicaid and exchange business [3][4] Analyst Commentary - Analyst Ryan Langston from TD Cowen noted that the cautious outlook reflects concerns regarding Medicaid and the value-based care (VBC) environment [4] - Astrana Health is characterized as a physician-centered, technology-powered healthcare company focused on delivering coordinated, high-quality care [4]